Search results
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
The Motley Fool via AOL· 4 days agoAstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 6 hours agoData from the phase 2 study is due later this year. Expect the stock to get a healthy bump if the...
3 No-Brainer Stocks to Buy in June
The Motley Fool via AOL· 1 day agoTrading at 18 times its expected future earnings, the stock's valuation is attractive when compared to the average healthcare stock, which trades at a forward-earnings ...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
Motley Fool via Yahoo Finance· 5 days agoBut if you're interested in a blue chip stock with big plans, it's a good option to invest in....
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
Motley Fool via Yahoo Finance· 5 days agoAnd there's nothing that's more core to a pharma business than a healthy pipeline. So, based on...
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Lifted by Hsbc Holdings PLC
ETF DAILY NEWS· 4 days agoHsbc Holdings PLC raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.7% during the fourth quarter, according to its most recent Form 13F filing with the ...
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Benzinga via AOL· 6 days agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the...
AstraZeneca stock upgraded by Goldman, 27% upside seen By Investing.com
Investing.com· 4 days agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN)...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Morningstar· 4 days agoGoldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral. Analysts led by Rajan Sharma said AstraZeneca
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 3 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
